All Articles

BriaCell Is Bringing New Breakthroughs To Breast Cancer

December 26, 2023
x min read

A publicly traded biotechnology company might have just made a significant breakthrough in treating advanced breast cancer.

What’s happening:

  • Clincal stage cancer biotechnology company BriaCell Therapeutics (NASDAQ: BCTX) has announced new positive data from their Phase II clinical trial for patients with advanced breast cancer
  • The new data illuminates that a subset of patients who have advanced breast cancer got significant benefit from BriaCell’s Bria-IMT treatment despite previously failing to respond to Antibody-Drug Conjugates

Why it matters:

  • Antibody-Drug Conjugates are one of the more significant recent advancements in cancer treatments but many patients either don’t respond favourably or experience serious side effects
  • Finding new ways to effectively treat patients with advanced breast cancer remains one of the largest challenges needing to be solved for in cancer therapy as a whole

Going deeper:

  • The new clinical data suggests BriaCell’s novel immunotherapy Bria-IMT could potentially be a breakthrough for treating patients with advanced breast cancer

By the numbers:

  • Of 23 patients with advanced breast cancer in BriaCell’s clinical trial who had not responded to Antibody-Drug Conjugates, 17 of them are still alive presently after BriaCell’s Bria-IMT treatment
  • 0 of the patients in the clinical trial reported any cases of Interstitial Lung Disease, which is an extremely common side effect of Antibody-Drug Conjugates
  • There was a 40% disease control rate in patients in the clinical trial, which is more compelling validation of the clinical benefit of Bria-IMT

Discover what’s next. The world’s biggest ideas, disruptive trends, most exciting early stage companies and groundbreaking entrepreneurs.

By clicking Subscribe you're confirming that you agree with our Privacy Policy.
Thanks for subscribing!
Keep an eye out for a welcome email shortly.
Oops! Something went wrong while submitting the form.